Novo Nordisk to Pay Up to $2 Billion for Rights to Experimental Obesity and Diabetes Drug
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...
Durham Herald Sun4h
Who are Raleigh’s and Durham’s largest employers? Which rise and fall on NC jobs lists?
Which company has replaced IBM as the largest employer in Research Triangle Park? And who are the top hirers in Wake, Durham, ...
NBC Los Angeles6h
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...